|Bid||27.5000 x 500|
|Ask||28.0000 x 200|
|Day's Range||27.5000 - 28.1300|
|52 Week Range||8.6600 - 28.4500|
|PE Ratio (TTM)||1,334.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Harry Boxer focuses on Exelixis, ImmunoGen and Impax Laboratories.
Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.
Which is the better growth stock going forward -- Exelixis or Incyte? It depends.